Beam Therapeutics Inc. (BEAM) stock
Close on Nov 11, 2026Market cap $2.67BP/E –Yield –
Beam Therapeutics Inc. grew revenue 158.9% to $156.04M over the twelve months to Jun 30, 2026. Free cash flow was -$372.77M. At the latest close the market valued the company at $2.67B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.67B
- P/E ratio
- –
- Price to sales
- 17.09
- Price to book
- 2.50
- Dividend yield
- –
- Free cash flow yield
- -13.98%
Fundamentals
- Revenue
- $156.04M
- Net income
- -$85.43M
- EPS, diluted
- -$0.82
- Free cash flow
- -$372.77M
- Book value per share
- $10.23
- Diluted shares
- 104M
Trading
- Next earnings
- Feb 23, 2027 (estimated, before the open)
- Previous close
- $25.15
- Open
- $25.47
- Day's range
- $24.67 – $26.07
- Volume
- 1,584,189
- Average volume (20 days)
- 1,911,959
- Index membership
- Russell 2000 (since Mar 2020), Russell 3000 (since May 2020)
- Beta (5 years)
- 2.01
- 52-week range
- $20.23 – $38.26
- RSI (14 days)
- 49.9
- Volatility (1 year)
- 72.2%
- Relative volume
- 0.81×
- WACC
- 14.6%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BEAM | S&P 500 | Difference | BEAM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.4% | -2.4% | +2.8 pts | ||
| 3 months | -3.9% | -1.2% | −2.7 pts | ||
| Year to date | -6.9% | +12.3% | −19.2 pts | ||
| 1 year | +14.8% | +12.4% | +2.4 pts | ||
| 3 years | +16.5% | +78.8% | −62.3 pts | +5.2% | +21.4% |
| 5 years | -72.4% | +75.2% | −147.5 pts | -22.7% | +11.9% |
| 10 years | -69.1% | +311.1% | −380.2 pts | -11.1% | +15.2% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Beam Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Beam Therapeutics
Biological Products, (No Diagnostic Substances)
Beam Therapeutics Inc. operates as a biotechnology research and development company that develops therapeutic programs and gene editing technologies. The company collaborates with pharmaceutical and biotechnology partners, including Pfizer, Eli Lilly, Apellis Pharmaceuticals, Verve Therapeutics, Orbital Therapeutics, and Prime Medicine. It enters into research agreements, licensing deals, and product development partnerships with academic institutions such as Harvard University and the Broad Institute to discover and advance therapies. Through these collaborative arrangements and development agreements, Beam Therapeutics focuses on advancing experimental therapies and technology platforms alongside its industry and academic counterparties.
Company profile, executives and historyBeam Therapeutics stock: common questions
What is Beam Therapeutics's stock price?
BEAM closed at $25.81 on Nov 11, 2026, up 2.62% on the day. Over the past 52 weeks it traded between $20.23 and $38.26.
What is Beam Therapeutics's market cap?
Beam Therapeutics was worth $2.67B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BEAM's P/E ratio?
Beam Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.82), so it has no meaningful P/E ratio.
How much revenue does Beam Therapeutics make?
Beam Therapeutics reported revenue of $156.04M for the twelve months to Jun 30, 2026, up 158.9% from a year earlier.
Does Beam Therapeutics pay a dividend?
No. Beam Therapeutics has not paid a cash dividend over the last twelve months.
When does Beam Therapeutics report earnings next?
Beam Therapeutics is expected to report Q4 FY2026 results on Feb 23, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has BEAM stock performed over the past year?
Including dividends, BEAM returned +14.8% over the past year, against +12.4% for the S&P 500.
How many BEAM shares are sold short?
26M shares were sold short at the latest FINRA report, 26.13% of the float, or 13.7 days of average trading volume.
Who are Beam Therapeutics's competitors?
Companies most similar to Beam Therapeutics by business, industry and size include AGEN, FDMT, MAZE, RGNX, DNA.
See a number that looks wrong?